MRK I-DXd PDUFA: First B7-H3 ADC in SCLC

Merck closed at $129.79 with a $322 billion market cap. On October 10, 2026, the FDA will decide on ifinatamab deruxtecan (I-DXd), the first B7-H3-directed antibody-drug conjugate for extensive-stage small cell lung cancer. I-DXd was discovered by Daiichi Sankyo and co-developed with Merck under a $4 billion upfront deal signed in October 2023 for three DXd-platform ADCs. The BLA has Priority Review and Breakthrough Therapy designation. Approval is likely. Merck’s stock will not react.

Here is why. I-DXd peak sales estimates fall in the $500 million to $1 billion range. Against Merck’s $16.3 billion in Q1 2026 revenue and $322 billion market cap, a $750 million drug is 0.2% of market cap and 4.6% of quarterly revenue at full penetration. This is a rounding error. Merck’s stock moves on KEYTRUDA biosimilar timing, Gardasil demand, and the pipeline transition away from the 2028 patent cliff. I-DXd is a pipeline brick, not a catalyst. For investors who want the ADC platform thesis, the pure play is Daiichi Sankyo (TSE: 4568), not Merck.

The disease context is where I-DXd gets interesting. Extensive-stage small cell lung cancer is one of the most aggressive solid tumors in oncology. The five-year survival rate is under 7%. Median overall survival hovers around one year. There are zero targeted therapies approved for second-line SCLC beyond tarlatamab, which won accelerated approval in May 2024 and full approval on November 19, 2025. Before tarlatamab, second-line options were topotecan and lurbinectedin, both cytotoxic chemotherapies with response rates of 10-20% and median survival of 8-10 months. SCLC has been a graveyard for targeted therapy for two decades.

I-DXd targets B7-H3, a transmembrane protein in the B7 checkpoint family that is overexpressed in 65% of SCLC tumors (IHC 2+/3+). B7-H3 expression correlates with larger tumors and shorter overall survival. It is minimally expressed in normal tissue, making it a clean ADC target. The drug uses Daiichi Sankyo’s DXd payload platform, the same topology that powers ENHERTU. We explained the antibody-drug conjugate mechanism in our primer. I-DXd consists of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload via a cleavable tetrapeptide linker. The linker releases the payload inside the cell after enzymatic cleavage.

The clinical data comes from the IDeate-Lung01 Phase 2 trial (ClinicalTrials.gov NCT05280470), published in the Journal of Clinical Oncology (doi:10.1200/JCO-25-02142). The trial enrolled 137 patients with previously treated ES-SCLC who received at least one prior line of platinum-based chemotherapy. The confirmed objective response rate was 48.2% (95% CI 39.6-56.9) by blinded independent central review. Three complete responses and 63 partial responses were observed. The disease control rate was 87.6%. Median duration of response was 5.3 months. Median progression-free survival was 4.9 months. Median overall survival was 10.3 months (95% CI 9.1-13.3).

The second-line subset is the number to watch. Among 32 patients who received I-DXd as second-line therapy, ORR was 56.3% (95% CI 37.7-73.6), median DOR was 7.2 months, and disease control rate was 96.9%. Among 105 patients in third-line and beyond, ORR was 45.7%. An exploratory analysis showed an intracranial ORR of 46.2% in 65 patients with brain metastases at baseline, which matters because SCLC metastasizes to the brain in 50-80% of patients and brain metastases carry a median OS of approximately 5 months.

The safety profile is manageable but not trivial. The dose-optimization phase of IDeate-Lung01 compared 8 mg/kg and 12 mg/kg doses. The 12 mg/kg dose was selected based on the ORR advantage (54.8% versus 26.1% at 8 mg/kg), but the higher dose carries more toxicity. The most common treatment-related adverse events with DXd-platform ADCs are interstitial lung disease (ILD), neutropenia, and thrombocytopenia. ILD is the class effect that has constrained every Daiichi ADC, including ENHERTU. In the IDeate-Lung01 trial, ILD events were monitored closely, and the 12 mg/kg dose showed a rate consistent with the broader DXd platform. The FDA will require an ILD risk evaluation and mitigation strategy (REMS) if approved, consistent with other DXd ADCs.

The competitive picture is tarlatamab. Amgen’s bispecific T-cell engager won full approval on November 19, 2025, based on the Phase 3 DeLLphi-304 trial. Tarlatamab achieved an ORR of 35% (versus 20% for chemotherapy), median OS of 13.6 months (HR 0.60, p<0.001), and median PFS of 4.2 months. The comparison is imperfect because I-DXd’s data is Phase 2 single-arm and tarlatamab’s is Phase 3 randomized. But the ORR difference is striking: 48.2% for I-DXd versus 35% for tarlatamab. I-DXd’s median OS of 10.3 months is lower than tarlatamab’s 13.6 months, though the confidence interval (9.1-13.3) approaches it. Direct cross-trial comparison is not valid, but these are the numbers the FDA and investors will use.

The market positioning question is whether I-DXd and tarlatamab compete or coexist. Tarlatamab is a bispecific T-cell engager requiring inpatient administration for the first cycle, with cytokine release syndrome and neurotoxicity as class effects. I-DXd is a conventional ADC administered as an IV infusion every three weeks with a more familiar safety profile for oncologists. In practice, oncologists may sequence the two: tarlatamab for patients who can tolerate immune activation, I-DXd for patients with brain metastases (where I-DXd’s 46.2% intracranial ORR is notable) or those who cannot manage the CRS risk. The SCLC market is small enough that two drugs can coexist without direct cannibalization, and both address a population that had zero targeted options two years ago.

The Phase 3 confirmatory trial, IDeate-Lung02, is ongoing with dual primary endpoints of ORR by BICR and overall survival. This is the binary event that will determine whether I-DXd becomes a standard of care or a niche option. If IDeate-Lung02 confirms the 48% ORR and shows an OS benefit, I-DXd could compete head-to-head with tarlatamab. If it misses, the drug retains its approval but loses credibility for broader adoption.

The B7-H3 target validation story extends beyond SCLC. GSK’s risvutatug rezetecan (ris-rez), another B7-H3 ADC, hit a Phase 3 win in osteosarcoma, as we covered in our ris-rez analysis. B7-H3 is becoming a validated target across multiple tumor types, which is significant because there are currently zero B7-H3-directed medicines approved for any cancer. I-DXd would be the first. The oncology catalysts roundup and the Q4 FDA calendar both flag October 10 as a key date.

The risk is Phase 2 single-arm data. The FDA granted Breakthrough Therapy designation and is reviewing under the Real-Time Oncology Review program and Project Orbis, both of which signal the agency sees urgency. But single-arm data in a heavily pretreated population is not the same as randomized Phase 3 data. The FDA may require post-marketing commitments from the ongoing IDeate-Lung02 trial. Accelerated approval is the most likely pathway, not full approval. That means I-DXd enters the market with a confirmatory trial hanging over it, and the binary risk does not fully resolve on October 10.

The verdict is split. For Merck, this is a hold regardless of outcome. I-DXd at $500 million to $1 billion peak is immaterial to a $322 billion company. Merck’s stock will not move on October 10. If you own Merck for the KEYTRUDA franchise and pipeline transition, I-DXd is a footnote. If you are looking for how PDUFA dates work, October 10 is the goal date with possible early action.

For Daiichi Sankyo, I-DXd is the third DXd-platform drug after ENHERTU and patritumab deruxtecan (HER3-DXd). The DXd platform is the most productive ADC engine in oncology. Daiichi trades on the Tokyo Stock Exchange (TSE: 4568), which limits access for US-only investors, but the read-through is clear: every DXd approval validates the platform and de-risks the pipeline behind it. The real catalyst for Daiichi is not I-DXd’s approval but IDeate-Lung02’s readout, which will determine whether B7-H3 becomes a durable franchise or a single-indication niche.

For investors who want B7-H3 exposure through a US-listed stock, GSK is the alternative. GSK’s ris-rez already has Phase 3 data in osteosarcoma and is advancing in SCLC (ARTEMIS-008). But GSK at $106.6 billion faces the same immateriality problem as Merck. The cleanest way to play the B7-H3 thesis is to wait for I-DXd approval, watch the IDeate-Lung02 readout, and position in Daiichi Sankyo if you have international access. If you do not, the ADC platform thesis is best accessed through the Daiichi ADR or through Merck as a broad pipeline play with I-DXd as one of many assets. Either way, October 10 is a target validation event, not a stock-moving event.